EUVIMEDEUVIMED entdecken
Crossref

Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia

Tamer Othman iD, Paul Koller iD, Ni-Chun Tsai, Dongyun Yang, Hoda Pourhassan iD, Vaibhav Agrawal iD, Dat Ngo, Jason Chen iD, Leonardo Farol, Ricardo Spielberger, Firoozeh Sahebi, Monzr M Al Malki iD und 14 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Tamer Othman und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post‐HCT, but published clinical experience is primarily with the first‐generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second‐generation TKI (2G‐TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty‐six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G‐TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity ( p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G‐TKI: 576.0 days (range, 72–921) versus 254.5 days (range, 3–2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5‐year overall survival and progression‐free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post‐HCT TKI maintenance in a large real‐world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedMaintenance ChemotherapyPhiladelphia ChromosomePyridazinesImatinib MesylateImidazolesYoung AdultTransplantation, HomologousAdolescentTyrosine Kinase Inhibitors

Substanzen

Protein Kinase InhibitorsponatinibPyridazinesImatinib MesylateImidazolesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Department of Computational and Quantitative Sciences, Beckman Research Institute, City of Hope, Duarte, California, USA.
  • Department of Pharmacy, City of Hope National Medical Center, California, Duarte, USA.

ORCID-Profile: Tamer Othman, Paul Koller, Hoda Pourhassan, Vaibhav Agrawal, Jason Chen, Monzr M Al Malki, Amandeep Salhotra, Haris Ali, Shukaib Arslan, Ryotaro Nakamura, Vinod Pullarkat, Ibrahim Aldoss, Matthew Mei

Zitieren

APA

Othman, T., Koller, P., Tsai, N. C., Yang, D., Pourhassan, H., Agrawal, V., Ngo, D., Chen, J., Farol, L., Spielberger, R., Sahebi, F., Al Malki, M. M., Cai, J. L., Sandhu, K. S., Mansour, J., Salhotra, A., Ali, H., Aribi, A., Arslan, S., …, & Mei, M. (2024). Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27378

Vancouver

Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, et al. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27378

BibTeX
@article{Othman2024,
  author = {Othman, Tamer and Koller, Paul and Tsai, Ni-Chun and Yang, Dongyun and Pourhassan, Hoda and Agrawal, Vaibhav and Ngo, Dat and Chen, Jason and Farol, Leonardo and Spielberger, Ricardo and Sahebi, Firoozeh and Al Malki, Monzr M and Cai, Ji-Lian and Sandhu, Karamjeet S and Mansour, Joshua and Salhotra, Amandeep and Ali, Haris and Aribi, Ahmed and Arslan, Shukaib and Marcucci, Guido and Forman, Stephen J and Stein, Anthony S and Nakamura, Ryotaro and Pullarkat, Vinod and Aldoss, Ibrahim and Mei, Matthew},
  title = {Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27378}
}
Kostenlos starten →